Caren van Roekel

173 Dose-response relationship in 166 Ho-radioembolization There was a significant difference in tumor absorbed dose between patients that showed no response (PD or STBD) and patients from the CRPR group (p=0.008). Metabolic response at a whole liver level, considering the development of new tumors as well, was as follows: there were 2 patients with CR, 10 patients with PR, 7 patients with STBD and 17 patients with PD. There were 3 patients with new intrahepatic tumors, 2 patients with new extrahepatic tumors and 5 patients with both new extra- and intrahepatic tumors. Survival Median overall survival was 13.5 months (range 2-31 months; 95% confidence interval 10-16 months). Median survival was significantly longer in responders (CRPR patients) (19 months, range 8-31 months) compared with non-responders (7,5 months, range 2-27 months) (Log-rank; p=0.01) (Figure 1). Baseline characteristics of both groups were explored, but no clearly distinguishable differences were evident (Table 1). FIGURE 3. (A) Median overall survival for entire study population was 13.5 months (range 2-31; 95% confidence interval 10-16 months). (B) Median survival in responders was significantly longer (19 months, range 8-31 months) than in non-responders (7.5 months, range 2-27 months) (Log-rank; p=0.01). 6